ECSP22022322A - Triazolopirimidinas como inhibidores de a2a/a2b - Google Patents
Triazolopirimidinas como inhibidores de a2a/a2bInfo
- Publication number
- ECSP22022322A ECSP22022322A ECSENADI202222322A ECDI202222322A ECSP22022322A EC SP22022322 A ECSP22022322 A EC SP22022322A EC SENADI202222322 A ECSENADI202222322 A EC SENADI202222322A EC DI202222322 A ECDI202222322 A EC DI202222322A EC SP22022322 A ECSP22022322 A EC SP22022322A
- Authority
- EC
- Ecuador
- Prior art keywords
- diseases
- triazolopyrimidines
- inhibitors
- activity
- subtypes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente solicitud se refiere a compuestos de la Fórmula (I): o estereoisómeros o sales farmacéuticamente aceptables de estos, que modulan la actividad de los receptores de adenosina, tales como los subtipos A2A y A2B, y son útiles para el tratamiento de enfermedades relacionadas con la actividad de los receptores de adenosina, que incluyen, por ejemplo, cáncer, enfermedades inflamatorias, enfermedades cardiovasculares y enfermedades neurodegenerativas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962891685P | 2019-08-26 | 2019-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP22022322A true ECSP22022322A (es) | 2022-05-31 |
Family
ID=72422275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202222322A ECSP22022322A (es) | 2019-08-26 | 2022-03-24 | Triazolopirimidinas como inhibidores de a2a/a2b |
Country Status (18)
Country | Link |
---|---|
US (2) | US20210061809A1 (es) |
EP (1) | EP4021907A1 (es) |
JP (1) | JP2022545923A (es) |
KR (1) | KR20220066074A (es) |
CN (1) | CN114585625A (es) |
AR (1) | AR119822A1 (es) |
AU (1) | AU2020337350A1 (es) |
BR (1) | BR112022003408A2 (es) |
CA (1) | CA3150766A1 (es) |
CL (1) | CL2022000457A1 (es) |
CO (1) | CO2022003457A2 (es) |
CR (1) | CR20220124A (es) |
EC (1) | ECSP22022322A (es) |
IL (1) | IL290529A (es) |
MX (1) | MX2022002219A (es) |
PE (1) | PE20230372A1 (es) |
TW (1) | TW202115082A (es) |
WO (1) | WO2021041360A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019168847A1 (en) | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
AU2019297361A1 (en) | 2018-07-05 | 2021-02-25 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
US20230159541A1 (en) * | 2021-11-19 | 2023-05-25 | Crossignal Therapeutics, Inc. | Adenosine receptor antagonists |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
WO1998042711A1 (fr) * | 1997-03-24 | 1998-10-01 | Kyowa Hakko Kogyo Co., Ltd. | DERIVES [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINIQUES |
ES2342240T3 (es) | 1998-08-11 | 2010-07-02 | Novartis Ag | Derivados de isoquinolina con actividad que inhibe la angiogenia. |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
MXPA04002243A (es) | 2001-09-19 | 2004-06-29 | Aventis Pharma Sa | Compuestos quimicos. |
CN1582150B (zh) | 2001-10-30 | 2011-09-07 | 诺瓦提斯公司 | 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物 |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
CN110446712B (zh) * | 2017-04-07 | 2021-09-14 | 南京明德新药研发有限公司 | 作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物 |
CN109535161B (zh) * | 2017-09-22 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用 |
WO2019168847A1 (en) * | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
CN112105617B (zh) * | 2018-04-28 | 2022-04-05 | 南京明德新药研发有限公司 | 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法 |
CA3100731A1 (en) * | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
AR116315A1 (es) * | 2018-09-12 | 2021-04-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos de triazolo-pirimidina y usos de los mismos |
AU2019383948A1 (en) * | 2018-11-20 | 2021-05-20 | Merck Sharp & Dohme Llc | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
US20220040184A1 (en) * | 2018-11-20 | 2022-02-10 | Merck Sharp Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
-
2020
- 2020-08-25 WO PCT/US2020/047714 patent/WO2021041360A1/en unknown
- 2020-08-25 CR CR20220124A patent/CR20220124A/es unknown
- 2020-08-25 US US17/002,045 patent/US20210061809A1/en not_active Abandoned
- 2020-08-25 BR BR112022003408A patent/BR112022003408A2/pt unknown
- 2020-08-25 EP EP20768191.7A patent/EP4021907A1/en active Pending
- 2020-08-25 CN CN202080068863.6A patent/CN114585625A/zh active Pending
- 2020-08-25 AR ARP200102383A patent/AR119822A1/es unknown
- 2020-08-25 PE PE2022000278A patent/PE20230372A1/es unknown
- 2020-08-25 AU AU2020337350A patent/AU2020337350A1/en active Pending
- 2020-08-25 KR KR1020227009865A patent/KR20220066074A/ko unknown
- 2020-08-25 TW TW109128933A patent/TW202115082A/zh unknown
- 2020-08-25 JP JP2022513216A patent/JP2022545923A/ja active Pending
- 2020-08-25 MX MX2022002219A patent/MX2022002219A/es unknown
- 2020-08-25 CA CA3150766A patent/CA3150766A1/en active Pending
-
2022
- 2022-02-10 IL IL290529A patent/IL290529A/en unknown
- 2022-02-24 CL CL2022000457A patent/CL2022000457A1/es unknown
- 2022-03-24 EC ECSENADI202222322A patent/ECSP22022322A/es unknown
- 2022-03-24 CO CONC2022/0003457A patent/CO2022003457A2/es unknown
- 2022-12-08 US US18/077,610 patent/US20230124485A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3150766A1 (en) | 2021-03-04 |
AU2020337350A1 (en) | 2022-03-10 |
MX2022002219A (es) | 2022-06-14 |
JP2022545923A (ja) | 2022-11-01 |
BR112022003408A2 (pt) | 2022-05-17 |
CN114585625A (zh) | 2022-06-03 |
IL290529A (en) | 2022-04-01 |
KR20220066074A (ko) | 2022-05-23 |
PE20230372A1 (es) | 2023-03-06 |
TW202115082A (zh) | 2021-04-16 |
EP4021907A1 (en) | 2022-07-06 |
US20230124485A1 (en) | 2023-04-20 |
CO2022003457A2 (es) | 2022-05-20 |
WO2021041360A1 (en) | 2021-03-04 |
US20210061809A1 (en) | 2021-03-04 |
AR119822A1 (es) | 2022-01-12 |
CR20220124A (es) | 2022-06-15 |
CL2022000457A1 (es) | 2022-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020011908A2 (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a/a2b | |
CO2021001251A2 (es) | Derivados de pirazina fusionados como inhibidores de a2a/a2b | |
CO2022003457A2 (es) | Triazolopirimidinas como inhibidores de a2a/a2b | |
ECSP21008112A (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
ECSP21063186A (es) | Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b | |
UY37124A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
CR20150633A (es) | Derivados del bipirazol como inhibidores jak | |
UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
ECSP17021897A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
ECSP20061378A (es) | COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma | |
CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
CL2020001047A1 (es) | Derivados de imidazol condensado sustituidos por grupos de hidroxia terciaria como inhibidores pi3k-gamma. | |
CU24627B1 (es) | Derivados de imidazolidin-2-ona sustituidos como inhibidores de prmt5 | |
CO2021008117A2 (es) | Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina | |
CL2020001461A1 (es) | Inhibidores de dopamina–b–hidroxilasa. | |
AR117605A1 (es) | Derivados de pirazina fusionados como inhibidores de a2a / a2b | |
EA202092016A1 (ru) | Имидазопиримидины и триазолопиримидины в качестве ингибиторов a2a/a2b | |
EA202190204A1 (ru) | Производные конденсированных пиразинов как ингибиторы a2a/a2b |